Enteris And Sanofi Combine To Treat Diabetes
Enteris BioPharma, Inc., has announced the initiation of a feasibility study agreement with Sanofi to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to develop an oral formulation of one of Sanofi’s preclinical stage peptides.
Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, remarked, “Our agreement with Sanofi is further validation of the tremendous value our Peptelligence platform program offers in the therapeutic peptide field. We are excited to work with an industry leader like Sanofi.”
This article has been republished from materials provided by Enteris. Note: material may have been edited for length and content. For further information, please contact the cited source.
Antimalarial Drugs Could Offer Clinical Benefit to Cancer PatientsNews
Antimalarial drugs chloroquine and hydroxychloroquine could find another use as cancer treatments, according to a new clinical study published in ecancermedicalscience.READ MORE
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE